Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 2/2008

Open Access 01-02-2008 | Case Report

A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma

Authors: F. H. Swaneveld, R. M. van Vugt, J. P. de Boer, B. A. C. Dijkmans, W. F. Lems

Published in: Clinical Rheumatology | Issue 2/2008

Login to get access

Abstract

Rituximab is a chimeric human-mouse anti-CD20 monoclonal antibody, which is used in the treatment of both B-cell lymphomas and rheumatic diseases. We describe a case of a previously healthy 57-year-old man developing arthritis while being treated with rituximab-CHOP chemotherapy (R-CHOP) for a non-Hodgkin lymphoma. The remittant arthritis developed at successively shorter time-intervals after R-CHOP administration and only improved after rituximab was removed from the chemotherapy schedule, suggesting a rituximab-related phenomenon, as extensive diagnostic testing ruled out any other diagnosis.
Literature
1.
Buda-Okreglak EM, Drabick JJ, Delaney NR (2004) Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom’s macroglobulinemia treated with rituximab. Ann Hematol 83:117–119PubMedCrossRef
2.
Pijpe J, van Imhoff GW, Spijkervet FKL, Roodenburg JLN, Wolbink GJ, Mansour K et al (2005) Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase ii study. Arthritis Rheum 52(9):2740–2750PubMedCrossRef
3.
Jardin F, Levesque H, Tilly H (2005) Auto-immune manifestations in Non-Hodgkin’s lymphoma. Rev Med Interne 26(7):557–571PubMed
4.
Kruger R, Oden J, de Leon F, Durr W (1993) Malignant non-Hodgkin’s lymphoma of the joint. Report of two cases, review of the literature and problems of classification. Unfallchirurg 96(10):556–562PubMed
5.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581PubMedCrossRef
6.
Maeda T, Yamada Y, Tawara M, Yamasaki R, Yakata Y, Tsutsumi C et al (2001) Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol 74(1):70–75PubMedCrossRef
Metadata
Title
A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma
Authors
F. H. Swaneveld
R. M. van Vugt
J. P. de Boer
B. A. C. Dijkmans
W. F. Lems
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0704-0

Other articles of this Issue 2/2008

Clinical Rheumatology 2/2008 Go to the issue

Original Article

Characteristic electron microscopic findings in the skin of patients with fibromyalgia—preliminary study

Original Article

Significance of anti-cell membrane-associated DNA (mDNA) antibodies in systemic lupus erythematosus

Original Article

Antioxidant enzyme activities, lipid peroxidation, and total antioxidant status in children with Henoch–Schönlein purpura

Case Report

Clostridium difficile: an under-recognized cause of reactive arthritis?

Case Report

Multiple peripheral arterial and aortic aneurysms in Behcet’s syndrome—a case report

Original Article

Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits